by John Conrad | Jul 15, 2019 | Policy News
iBIO commends Governor Pritzker for signing HB 2259 – Drug Therapeutic Advisory Board-Expands Membership-Biological Products. Approximately 30 million Americans suffer from one of nearly 7,000 rare diseases. Of those 7,000 diseases only 5% have treatments which...
by John Conrad | Jun 10, 2019 | Policy News, PolicyFeature1
iBIO promotes thoughtful legislative and regulatory solutions that allow our member companies to research, develop, and commercialize breakthrough therapies and cures, and to ensure patients have affordable access to those new treatments. Likewise, iBIO opposes...
by John Conrad | Apr 13, 2019 | Policy News
What Innovation Means to the Illinois Life Sciences Industry Today is Innovation day in Illinois. Innovation is critical to the life sciences industry in Illinois, because innovation in the life sciences industry extend lives, improve quality of life and drive value...
by Randy | Mar 6, 2019 | Policy News, PolicyFeature2
Last week, iBIO organized a trip to Washington for Illinois medical technology (MedTech) companies to meet with lawmakers and discuss how they can work together to provide patients greater access to next generation, life-saving products. The fly-in participants...
by John Conrad | Feb 28, 2019 | Policy News
The Illinois Biotechnology Innovation Organization (iBIO) believes the focus of the Illinois House Prescription Drug Affordability & Accessibility Committee is well intentioned relating to the legitimate concerns regarding access to affordable healthcare. However,...
by John Conrad | Jan 4, 2019 | Policy News
At the end of 2018 iBIO submitted comments on the proposed International Pricing IndEx (IPI) Model for Medicare Part B medicines. Medicare Part B supports the sickest, most vulnerable Medicare patients and only accounts for a small fraction of all Medicare Spending....
